Bristol-Myers Squibb Co., of New York, and the Institute of Research in Immunology and Cancer in Montreal identified a molecule acting on a “novel therapeutic target” that was undisclosed. Read More
Galderma SA, of Lausanne, Switzerland, said the European Commission granted marketing approval in Europe for Mirvaso (brimonidine) 3 mg/g gel. Read More
Altheus Therapeutics Inc., of Oklahoma City, said it completed dosing in ZA201, a double-blind, active-controlled phase II trial evaluating the efficacy and safety of Zoenasa rectal gel vs. mesalamine enema in 120 patients with left-sided ulcerative colitis. Read More
Dara Biosciences Inc., of Raleigh, N.C., said it received notice from Nasdaq that it has regained compliance with the minimum $1 bid price per share requirement. The company previously enacted a reverse stock split to regain compliance. Read More
Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said it intends to offer and sell shares of its common stock in an underwritten public offering. Piper Jaffray & Co. and Stifel, Nicolaus & Co. Inc. are acting as joint bookrunning managers for the offering. Read More
Aegerion Pharmaceuticals Inc., of Cambridge, Mass., reported net product sales of lomitapide of $24.5 million in in the fourth-quarter ended Dec. 31, 2013 and $48.5 million in the full-year. Read More
Talk about a great Act One. After six years quietly developing Laminin-111, a protein replacement therapy for ultra-rare merosin-deficient congenital muscular dystrophy (MDC1A), privately held Prothelia Inc. snagged leading rare disease firm Alexion Pharmaceuticals Inc. as its first strategic partner earlier this month in a three-way deal with the University of Nevada, Reno, where the technology was developed. Read More
LONDON – A compound found in a traditional Chinese medicine has anti-inflammatory properties and could point the way to a novel class of drugs, a study in zebrafish larvae has shown. Read More
Despite deep disagreement over some provisions in a proposed Medicare Part D rule, lawmakers on both sides of the aisle opposed the Centers for Medicare & Medicaid Services’ (CMS) proposal to remove immunosuppressants and antidepressants from protected class status. Read More
